Erika Hitre

11.7k total citations · 3 hit papers
60 papers, 5.5k citations indexed

About

Erika Hitre is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Erika Hitre has authored 60 papers receiving a total of 5.5k indexed citations (citations by other indexed papers that have themselves been cited), including 33 papers in Oncology, 18 papers in Pulmonary and Respiratory Medicine and 15 papers in Surgery. Recurrent topics in Erika Hitre's work include Colorectal Cancer Treatments and Studies (13 papers), Gastric Cancer Management and Outcomes (8 papers) and Breast Cancer Treatment Studies (8 papers). Erika Hitre is often cited by papers focused on Colorectal Cancer Treatments and Studies (13 papers), Gastric Cancer Management and Outcomes (8 papers) and Breast Cancer Treatment Studies (8 papers). Erika Hitre collaborates with scholars based in Hungary, United States and Spain. Erika Hitre's co-authors include Eric Van Cutsem, Gunnar Folprecht, Philippe Rougier, Claus-Henning Köhne, Tamás Pintér, Geert D’Haens, Anatoly Makhson, Jae Kyung Roh, Michael Schlichting and G. Bodoky and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Cancer.

In The Last Decade

Erika Hitre

59 papers receiving 5.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer

2009 2.9k citations Eric Van Cutsem, Claus-Henning Köhne et al. New England Journal of Medicine profile →
Prognostic and Predictive Value of Tumor-Infiltrating Lymphocytes in a Phase III Randomized Adjuvant Breast Cancer Trial in Node-Positive Breast Cancer Comparing the Addition of Docetaxel to Doxorubicin With Doxorubicin-Based Chemotherapy: BIG 02-98

2013 1.2k citations Sherene Loi, Nicolas Sirtaine et al. Journal of Clinical Oncology profile →
Cabozantinib for radioiodine-refractory differentiated thyroid cancer (COSMIC-311): a randomised, double-blind, placebo-controlled, phase 3 trial

2021 156 citations Marcia S. Brose, Bruce Robinson et al. The Lancet Oncology profile →

Peers

Countries citing papers authored by Erika Hitre

Since Specialization

Citations

This map shows the geographic impact of Erika Hitre's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Erika Hitre with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Erika Hitre more than expected).

Fields of papers citing papers by Erika Hitre

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Erika Hitre. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Erika Hitre. The network helps show where Erika Hitre may publish in the future.

Co-authorship network of co-authors of Erika Hitre

This figure shows the co-authorship network connecting the top 25 collaborators of Erika Hitre. A scholar is included among the top collaborators of Erika Hitre based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Erika Hitre. Erika Hitre is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Bemarituzumab as first-line treatment for locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma: final analysis of the randomized phase 2 FIGHT trial 2024 ·Gastric Cancer ·Zev A. Wainberg, Yoon‐Koo Kang, Keun‐Wook Lee, Shukui Qin, Kensei Yamaguchi, In‐Ho Kim, Anwaar Saeed, Sang Cheul Oh, Jin Li, Hacı Mehmet Türk, Alexandra Teixeira, Erika Hitre, (unknown), Giovanni Gerardo Cardellino, (unknown), Anita Zahlten‐Kumeli, Kate Taylor, Peter C. Enzinger	30
2	9P Positive ad hoc results from neoadjuvant Foxy-5 treatment of colon cancer patients in the ongoing phase II NeoFox study 2024 ·Annals of Oncology ·Rafaela Soler, (unknown), Ismael Macías, Alfonso Yubero, A. Bassam, Javier Gállego, Yousuf Al-Farhat, (unknown), Pilar Alfonso, (unknown), Ana Ruiz‐Casado, (unknown), Péter Árkosy, (unknown), (unknown), (unknown), (unknown), Erika Hitre, (unknown), (unknown)	1
3	Increased Progression-Free Survival with Cabozantinib Versus Placebo in Patients with Radioiodine-Refractory Differentiated Thyroid Cancer Irrespective of Prior Vascular Endothelial Growth Factor Receptor-Targeted Therapy and Tumor Histology: A Subgroup Analysis of the COSMIC-311 Study 2023 ·Thyroid ·Jaume Capdevila, Jolanta Krajewska, Jorge Hernando, Bruce Robinson, Steven I. Sherman, Barbara Jarząb, Chia‐Chi Lin, Fernanda Vaisman, Ana O. Hoff, Erika Hitre, Daniel W. Bowles, (unknown), Roman M. Levytskyy, Jennifer Oliver, Bhumsuk Keam, Marcia S. Brose	6
4	Cabozantinib for radioiodine-refractory differentiated thyroid cancer (COSMIC-311): a randomised, double-blind, placebo-controlled, phase 3 trial breakdown → 2021 ·The Lancet Oncology ·Marcia S. Brose, Bruce Robinson, Steven I. Sherman, Jolanta Krajewska, Chia‐Chi Lin, Fernanda Vaisman, Ana O. Hoff, Erika Hitre, Daniel W. Bowles, Jorge Hernando, Leonardo Faoro, Kamalika Banerjee, Jennifer Oliver, Bhumsuk Keam, Jaume Capdevila	156
5	Phase 3 multicenter, open-label, randomized study of infigratinib versus gemcitabine plus cisplatin in the first-line treatment of patients with advanced cholangiocarcinoma with FGFR2 gene fusions/translocations: the PROOF trial 2019 ·Annals of Oncology ·Milind Javle, Ivan Borbath, Stephen Clarke, Erika Hitre, Christophe Louvet, Teresa Macarulla, Do‐Youn Oh, Jennifer L. Spratlin, Juan Carlos del Valle, Karl Heinz Weiss, (unknown), Michael F. Howland, (unknown), (unknown), Susan Moran, Ghassan K. Abou‐Alfa	4
6	EndoTAG-1 plus gemcitabine versus gemcitabine alone in patients with measurable locally advanced and/or metastatic adenocarcinoma of the pancreas failed on FOLFIRINOX treatment 2019 ·Annals of Oncology ·Meng Su, (unknown), Erika Hitre, (unknown), Li‐Yuan Bai, Zsuzsanna Pápai, Seok Yun Kang, Mikhail Dvorkin, Min‐Hsien Lee, (unknown), (unknown), (unknown), G. Bodoky, Pascal Artru, Jun‐Eul Hwang, I. Bazin, (unknown), Jean‐Baptiste Bachet, Zsolt Horváth, Chirn‐Bin Chang, Johnson Lin	4
7	Predictive Value of Early Skin Rash in Cetuximab-Based Therapy of Advanced Biliary Tract Cancer 2017 ·Pathology & Oncology Research ·Gábor Rubovszky, Barna Budai, (unknown), Zsolt Horváth, É Juhos, (unknown), Tünde Nagy, Eszter Szabó, Tamás Pintér, Erika Tóth, Péter Nagy, István Láng, Erika Hitre	5
8	Prognostic and Predictive Value of Tumor-Infiltrating Lymphocytes in a Phase III Randomized Adjuvant Breast Cancer Trial in Node-Positive Breast Cancer Comparing the Addition of Docetaxel to Doxorubicin With Doxorubicin-Based Chemotherapy: BIG 02-98 breakdown → 2013 ·Journal of Clinical Oncology ·Sherene Loi, Nicolas Sirtaine, Fanny Piette, Roberto Salgado, Giuseppe Viale, (unknown), Ghizlane Rouas, Prudence A. Francis, John Crown, Erika Hitre, Evandro de Azambuja, Emmanuel Quinaux, Angelo Di Leo, Stefan Michiels, Martine Piccart, Christos Sotiriou	1213
9	Cetuximab, gemcitabine and capecitabine in patients with inoperable biliary tract cancer: A phase 2 study 2013 ·European Journal of Cancer ·Gábor Rubovszky, István Láng, (unknown), Zsolt Horváth, É Juhos, Tünde Nagy, Eszter Szabó, (unknown), Barna Budai, Erika Hitre	34
10	Cetuximab and platinum-based chemoradio- or chemotherapy of patients with epidermal growth factor receptor expressing adenoid cystic carcinoma: a phase II trial 2013 ·British Journal of Cancer ·Erika Hitre, Barna Budai, Zoltán Takácsi‐Nagy, Gábor Rubovszky, Erika Tóth, Éva Remenár, Csaba Polgár, István Láng	54
11	Long-term outcomes with high-dose-rate brachytherapy for the management of base of tongue cancer 2013 ·Brachytherapy ·Zoltán Takácsi‐Nagy, (unknown), (unknown), Erika Hitre, Tibor Major, János Fodor, Csaba Polgár	21
12	Impact of SHMT1 polymorphism on the clinical outcome of patients with metastatic colorectal cancer treated with first-line FOLFIRI+bevacizumab 2011 ·Pharmacogenetics and Genomics ·Barna Budai, (unknown), Vilmos Adleff, (unknown), (unknown), Tünde Nagy, Judit Kralovánszky, István Láng, Erika Hitre	19
13	Inflammatory Breast Cancer—Comparing the Effectivity of Preoperative Docetaxel-Epirubicine Protocol to Conventional Antracycline-Containing Chemotherapy to Achieve Clinical Benefit and Complete Pathological Response 2010 ·Pathology & Oncology Research ·Zsolt Horváth, László Torday, Erika Hitre, (unknown), É Juhos, (unknown), László Urbán, Csaba Polgár, István Láng, (unknown), Miklós Kásler	4
14	A case-control study of gallbladder cancer in hungary. 2009 ·PubMed ·Hiroto Nakadaira, István Láng, Zoltán Szentirmay, Erika Hitre, (unknown), Masaharu Yamamoto	14
15	Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer breakdown → 2009 ·New England Journal of Medicine ·Eric Van Cutsem, Claus-Henning Köhne, Erika Hitre, J. Załuski, (unknown), Anatoly Makhson, Geert D’Haens, Tamás Pintér, Robert Lim, G. Bodoky, Jae Kyung Roh, Gunnar Folprecht, Paul Ruff, Christopher Stroh, Sabine Tejpar, Michael Schlichting, Johannes Nippgen, Philippe Rougier	2902
16	Effects of the lactase 13910 C/T and calcium-sensor receptor A986S G/T gene polymorphisms on the incidence and recurrence of colorectal cancer in Hungarian population 2008 ·BMC Cancer ·Krisztián Bácsi, Erika Hitre, János P. Kósa, Henrik Csaba Horváth, Áron Lazáry, Péter L. Lakatos, Bernadett Balla, Barna Budai, Gábor Speer	25
17	Common NOD2/CARD15 variants are not associated with susceptibility or the clinicopathologic characteristics of sporadic colorectal cancer in Hungarian patients 2007 ·BMC Cancer ·Péter L. Lakatos, Erika Hitre, Ferenç Szalay, (unknown), (unknown), Simon Fischer, J Osztovits, (unknown), Gábor Veres, J. Papp, Peter Ferenci	26
18	[Trastuzumab (Herceptin) in the adjuvant treatment of HER-2-positive early breast cancer]. 2006 ·PubMed ·István Láng, Erika Hitre	2
19	Influence of thymidylate synthase gene polymorphisms on the survival of colorectal cancer patients receiving adjuvant 5-fluorouracil 2005 ·Pharmacogenetics and Genomics ·Erika Hitre, Barna Budai, Vilmos Adleff, (unknown), Zsolt Horváth, (unknown), József Lövey, Tibor Kovács, Zsolt Orosz, István Láng, Miklós Kásler, Judit Kralovánszky	56
20	Heterozygote deficiency in thymidylate synthase enhancer region polymorphism genotype distribution in Hungarian colorectal cancer patients 2004 ·International Journal of Cancer ·Vilmos Adleff, Erika Hitre, (unknown), Zsolt Orosz, (unknown), Judit Kralovánszky	33

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact